172 related articles for article (PubMed ID: 32588078)
1. Fear expression is reduced after acute and repeated nociceptin/orphanin FQ (NOP) receptor antagonism in rats: therapeutic implications for traumatic stress exposure.
Taylor RM; Jeong IH; May MD; Bergman EM; Capaldi VF; Moore NLT; Matson LM; Lowery-Gionta EG
Psychopharmacology (Berl); 2020 Oct; 237(10):2943-2958. PubMed ID: 32588078
[TBL] [Abstract][Full Text] [Related]
2. Mitigation of adverse behavioral impact from predator exposure by the nociceptin/orphanin FQ peptide antagonist J-113397 in rats.
Genovese RF; Dobre S
Behav Pharmacol; 2017 Oct; 28(7):521-530. PubMed ID: 28704271
[TBL] [Abstract][Full Text] [Related]
3. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.
Zhang Y; Simpson-Durand CD; Standifer KM
Br J Pharmacol; 2015 Jan; 172(2):571-82. PubMed ID: 24666365
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the NOP receptor signaling affects resilience to acute stress.
Holanda VAD; Pacifico S; Azevedo Neto J; Finetti L; Lobão-Soares B; Calo G; Gavioli EC; Ruzza C
J Psychopharmacol; 2019 Dec; 33(12):1540-1549. PubMed ID: 31337258
[TBL] [Abstract][Full Text] [Related]
5. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin and the nociceptin receptor in learning and memory.
Andero R
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():45-50. PubMed ID: 25724763
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
8. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
[TBL] [Abstract][Full Text] [Related]
9. Participation of the nociceptin/orphanin FQ receptor in ethanol-mediated locomotor activation and ethanol intake in preweanling rats.
Miranda-Morales RS; Nizhnikov ME; Waters DH; Spear NE
Behav Brain Res; 2013 May; 245():137-44. PubMed ID: 23439216
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
Marti M; Mela F; Budri M; Volta M; Malfacini D; Molinari S; Zaveri NT; Ronzoni S; Petrillo P; Calò G; Morari M
Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
[TBL] [Abstract][Full Text] [Related]
11. Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.
Rekik K; Faria Da Silva R; Colom M; Pacifico S; Zaveri NT; Calo' G; Rampon C; Frances B; Mouledous L
Neuropharmacology; 2017 Oct; 125():39-49. PubMed ID: 28705439
[TBL] [Abstract][Full Text] [Related]
12. Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD.
Andero R; Brothers SP; Jovanovic T; Chen YT; Salah-Uddin H; Cameron M; Bannister TD; Almli L; Stevens JS; Bradley B; Binder EB; Wahlestedt C; Ressler KJ
Sci Transl Med; 2013 Jun; 5(188):188ra73. PubMed ID: 23740899
[TBL] [Abstract][Full Text] [Related]
13. Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress.
Silva AI; Holanda VAD; Azevedo Neto JG; Silva Junior ED; Soares-Rachetti VP; Calo G; Ruzza C; Gavioli EC
Psychopharmacology (Berl); 2020 Jun; 237(6):1633-1642. PubMed ID: 32095915
[TBL] [Abstract][Full Text] [Related]
14. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
16. Exploring LPS-induced sepsis in rats and mice as a model to study potential protective effects of the nociceptin/orphanin FQ system.
Thomas RC; Bath MF; Stover CM; Lambert DG; Thompson JP
Peptides; 2014 Nov; 61():56-60. PubMed ID: 25161013
[TBL] [Abstract][Full Text] [Related]
17. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
18. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions.
Awwad HO; Durand CD; Gonzalez LP; Tompkins P; Zhang Y; Lerner MR; Brackett DJ; Sherry DM; Awasthi V; Standifer KM
Behav Brain Res; 2018 Mar; 340():183-194. PubMed ID: 27793733
[TBL] [Abstract][Full Text] [Related]
19. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Jiang F; Chiou LC
Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
[TBL] [Abstract][Full Text] [Related]
20. Recovery from Traumatic Brain Injury Is Nociceptin/Orphanin FQ Peptide Receptor Genotype-, Sex-, and Injury Severity-Dependent.
Al Yacoub ON; Awwad HO; Standifer KM
J Pharmacol Exp Ther; 2024 Apr; 389(2):136-149. PubMed ID: 37442620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
